Liquid biopsy opportunity Exosome Diagnostics focuses on minimally invasive molecular diagnostics using exosomes from blood and urine to guide cancer therapies, presenting a clear upsell path to labs and clinics aiming to implement liquid biopsy workflows.

Expansion through partnerships Recent and historical collaborations (e.g., Intezyne, Bio-Techne integration) indicate openness to co-development and joint validation efforts, suggesting strategic alliance opportunities for co-marketing, distribution, and assay co-development.

Regulatory and scientific credibility Publications in high-profile journals and leadership appointments (Head of Medical Affairs) provide credibility that can accelerate payer discussions, clinical adoption, and hospital procurement conversations.

Integrated tech stack Utilizes industry-standard platforms (Microsoft 365, Google Cloud, Marketo, Drupal/WordPress) which simplifies integration with customer-facing portals, CRM workflows, and marketing automation for faster lead nurturing and order processing.

Scale potential and funding Revenue range and substantial funding indicate growth capability, presenting opportunities to upsell premium services, informatics, and expanded panel offerings to larger oncology centers and research institutions.